Page last updated: 2024-10-31

metyrapone and Leukemia

metyrapone has been researched along with Leukemia in 1 studies

Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.
metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.

Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nakamura, M1

Other Studies

1 other study available for metyrapone and Leukemia

ArticleYear
[Treatment with massive doses of synthetic corticoids and hypothalamopituitary adrenocortical function with reference to acute leukemia].
    Nihon Naibunpi Gakkai zasshi, 1968, Jan-20, Volume: 43, Issue:10

    Topics: 17-Hydroxycorticosteroids; Acute Disease; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Beta

1968